BACKGROUND: The purpose of this study was to examine the rate of and risks for cervical human papillomavirus type 16 (HPV16) redetection in women with documented or suspected HPV16 infection. METHODS: A convenience sample of women aged 13-21 years were seen at 4-month intervals for HPV DNA testing and cytology. Serum samples were obtained at baseline and annually. RESULTS: A total of 1543 women entered the study. Of the 295 women with detection of HPV16 DNA and subsequent clearance, 18.1% had HPV16 redetected by 8.5 years (88% cleared this second detection by 3 years). Of the 247 women who had antibodies to HPV16 and were HPV16 DNA negative at baseline, 15.3% had HPV16 redetected by year 5. Risks for redetection included douching, current use of medroxyprogesterone, reporting >1 sex partner or having a new sex partner, and having a sexually transmitted infection. Development of cervical intraepithelial neoplasia 2/3 was rare in women with redetection, except for those with prevalent HPV16 infection. CONCLUSIONS: Reappearance of HPV16 DNA was observed in 18% of women. Most are associated with sexual exposure and appear benign. Interpretation of the studies is more complex in women with prevalent infections as it appears that this small subset reflects women with persistence already present at entry.
BACKGROUND: The purpose of this study was to examine the rate of and risks for cervical human papillomavirus type 16 (HPV16) redetection in women with documented or suspected HPV16infection. METHODS: A convenience sample of women aged 13-21 years were seen at 4-month intervals for HPV DNA testing and cytology. Serum samples were obtained at baseline and annually. RESULTS: A total of 1543 women entered the study. Of the 295 women with detection of HPV16 DNA and subsequent clearance, 18.1% had HPV16 redetected by 8.5 years (88% cleared this second detection by 3 years). Of the 247 women who had antibodies to HPV16 and were HPV16 DNA negative at baseline, 15.3% had HPV16 redetected by year 5. Risks for redetection included douching, current use of medroxyprogesterone, reporting >1 sex partner or having a new sex partner, and having a sexually transmitted infection. Development of cervical intraepithelial neoplasia 2/3 was rare in women with redetection, except for those with prevalent HPV16infection. CONCLUSIONS: Reappearance of HPV16 DNA was observed in 18% of women. Most are associated with sexual exposure and appear benign. Interpretation of the studies is more complex in women with prevalent infections as it appears that this small subset reflects women with persistence already present at entry.
Entities:
Keywords:
reactivation; redetection of HPV16; risk for acquisition; risk for clearance
Authors: Anna-Barbara Moscicki; Stephen Shiboski; Nancy K Hills; Kimberly J Powell; Naomi Jay; Evelyn N Hanson; Susanna Miller; K Lisa Canjura-Clayton; Sepidah Farhat; Jeanette M Broering; Teresa M Darragh Journal: Lancet Date: 2004 Nov 6-12 Impact factor: 79.321
Authors: Tim Waterboer; Peter Sehr; Kristina M Michael; Silvia Franceschi; John D Nieland; Thomas O Joos; Markus F Templin; Michael Pawlita Journal: Clin Chem Date: 2005-08-11 Impact factor: 8.327
Authors: K Syrjänen; M Hakama; S Saarikoski; M Väyrynen; M Yliskoski; S Syrjänen; V Kataja; O Castrén Journal: Sex Transm Dis Date: 1990 Jan-Mar Impact factor: 2.830
Authors: A B Moscicki; S Shiboski; J Broering; K Powell; L Clayton; N Jay; T M Darragh; R Brescia; S Kanowitz; S B Miller; J Stone; E Hanson; J Palefsky Journal: J Pediatr Date: 1998-02 Impact factor: 4.406
Authors: Raphael P Viscidi; Mark Schiffman; Allan Hildesheim; Rolando Herrero; Philip E Castle; Maria C Bratti; Ana Cecilia Rodriguez; Mark E Sherman; Sophia Wang; Barbara Clayman; Robert D Burk Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-02 Impact factor: 4.254
Authors: Gloria Y F Ho; Yevgeniy Studentsov; Charles B Hall; Robert Bierman; Leah Beardsley; Michele Lempa; Robert D Burk Journal: J Infect Dis Date: 2002-08-28 Impact factor: 5.226
Authors: Shih-Wen Lin; Arpita Ghosh; Carolina Porras; Sarah C Markt; Ana Cecilia Rodriguez; Mark Schiffman; Sholom Wacholder; Troy J Kemp; Ligia A Pinto; Paula Gonzalez; Nicolas Wentzensen; Mark T Esser; Katie Matys; Ariane Meuree; Wim Quint; Leen-Jan van Doorn; Rolando Herrero; Allan Hildesheim; Mahboobeh Safaeian Journal: PLoS One Date: 2013-01-02 Impact factor: 3.240
Authors: Tsung-chieh Jane Fu; Long Fu Xi; Ayaka Hulbert; James P Hughes; Qinghua Feng; Stephen M Schwartz; Stephen E Hawes; Laura A Koutsky; Rachel L Winer Journal: Int J Cancer Date: 2015-05-29 Impact factor: 7.396
Authors: Nadja Vielot; Michael G Hudgens; Nelly Mugo; Michael Chitwa; Joshua Kimani; Jennifer Smith Journal: Sex Transm Dis Date: 2015-06 Impact factor: 2.830
Authors: Shitaldas J Pamnani; Staci L Sudenga; Raphael Viscidi; Dana E Rollison; B Nelson Torres; Donna J Ingles; Martha Abrahamsen; Luisa L Villa; Eduardo Lazcano-Ponce; Jorge Salmeron; Manuel Quiterio; Yangxin Huang; Amy Borenstein; Anna R Giuliano Journal: Cancer Res Date: 2016-08-17 Impact factor: 12.701
Authors: Thanh Cong Bui; Michael E Scheurer; Vy Thi-Tuong Pham; Ly Thi-Hai Tran; Leng Bun Hor; Damon J Vidrine; Michael W Ross; Christine M Markham Journal: J Med Virol Date: 2018-08-13 Impact factor: 2.327
Authors: S Rachel Skinner; Cosette M Wheeler; Barbara Romanowski; Xavier Castellsagué; Eduardo Lazcano-Ponce; M Rowena Del Rosario-Raymundo; Carlos Vallejos; Galina Minkina; Daniel Pereira Da Silva; Shelly McNeil; Vera Prilepskaya; Irina Gogotadze; Deborah Money; Suzanne M Garland; Viktor Romanenko; Diane M Harper; Myron J Levin; Archana Chatterjee; Brecht Geeraerts; Frank Struyf; Gary Dubin; Marie-Cécile Bozonnat; Dominique Rosillon; Laurence Baril Journal: Int J Cancer Date: 2016-05-15 Impact factor: 7.396